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Abstract: Mesothelioma is a rare malignancy arising from mesothe-
lial cells lining the pleura and peritoneum. Advances in modern
technology have allowed the development of array based approaches
to the study of disease allowing researchers the opportunity to study
many genes or proteins in a high-throughput fashion. This review
describes the current knowledge surrounding array based ap-
proaches with respect to mesothelioma research.
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Mesothelioma—Clinico–Pathological Features
Mesothelioma is a rare malignancy arising from me-
sothelial cells lining the pleura and peritoneum. For the
purposes of this review we shall concentrate on the most
common form of mesothelioma, malignant pleural mesothe-
lioma (MPM). Currently rates of MPM are rising and esti-
mates indicate that the incidence of MPM will peak within
the next 10 to 15 years for the western world,1,2 while
Japanese estimates are predicted to occur for approximately
40 years.3 Untreated, MPM has a median survival time of 6
months, and most patients die within 24 months of diagno-
sis.1,4 Historically, three distinct subtypes of MPM can be
distinguished based on histologic features: epithelial, sarco-
matoid and mixed/biphasic. Currently, a combination of pem-
etrexed and cisplatin is considered to be the standard of care
as a front line chemotherapy in MPM patients because it has
been shown to significantly improve response rates, time to
progression, overall survival, and quality of life when com-
pared with cisplatin alone.5,6
Treatment of MPM does not have one widely accepted
treatment modality, which has been exacerbated by a lack of
randomized clinical trials to compare available regimens.1
Currently treatment modalities include surgery Video-As-
sisted Thorascopy, pleurectomy/decortication or extrapleural
pneumonectomy, radiotherapy, or chemotherapy. For patients
with earlier stages of MPM, systemic chemotherapy and
more aggressive multimodal approaches, including chemo-
therapy, extrapleural pneumonectomy, and radiotherapy may
offer more effective treatment than stand alone treatment.6–8
However, the majority of patients with mesothelioma present
with advanced disease.6
Array Technologies—Types, Paradigms,
and Pitfalls
The advent of microarray technology has enabled re-
searchers to examine many genes or proteins from the same
sample simultaneously.9 Other uses for microarray technol-
ogy include the development of microarray-based techniques
for mapping disease loci using high-density single nucleotide
polymorphism (SNP)-genotyping arrays,10,11 and compara-
tive genomic hybridization arrays (array-CGH) to identify
chromosomal losses and gains within tumors.12
Microarray approaches have also been used to examine
the role of the regulatory chromatin environment relating to
aberrant gene expression in cancer, with the development of
chromatin immunoprecipitation -on-Chip arrays,13–15 CpG
island microarrays,16 and combining epigenetic inhibitors
with gene expression arrays.17,18
One of the most exciting uses of microarrays within the
clinical setting, is their potential use as (a) prognostic factors
for clinical outcome,19–23 (b) predictors of resistance to che-
motherapy,24 and (c) in pharmacogenomics of drug re-
sponse.25 In the adjuvant setting, to avoid missing the few
patients who may benefit from treatment, most cancer pa-
tients are currently overtreated. Potentially, microarray based
technologies within the clinical setting could allow personal-
ized therapies geared towards the individual and based on
their molecular profiles.26 However, a caveat to the current
potential of microarray based personalized therapies is that
many studies use samples which contain admixtures of stro-
mal or other cell types in addition to the tumor cells. This can
lead to complications not only in the precise delineation of
gene profiling between nontumor and tumor,27 but issues of
reproducibility and accuracy can consequently cause prob-
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lems with regulatory agencies.28,29 The other main problems
which have been associated with poor microarray reliability
and reproducibility stem from suboptimal array design and
incorrect probe annotations, which can be partly rectified
through well designed analysis.9
The ongoing difficulties for the use of microarray
technologies in the regulatory setting has resulted in the Food
and Drug Administration setting up a specific portal to
provide up-to-date regulatory and background information in
relation to genomic studies concerning biomarker identifica-
tion or pharmacogenomics.30,31 This increasing importance
for array reliability and reproducibility resulted in the setting
up by the Food and Drug Administration of a Microarray
Quality Control project (http://www.fda.gov/nctr/science/centers/
toxicoinformatics/maqc/), the results of which have recently
been published. These exciting developments indicate that
both intraplatform consistency and interplatform concordance
can be achieved, and represents the first important step in
establishing the acceptance of microarrays for use in clinical
and regulatory settings.32,33
In the following sections we shall describe the current
use of array technology in mesothelioma research.
Transcriptomic Analysis of Mesothelioma
Using Microarrays
The transcriptome can be described as “a collection of
all the gene transcripts present in a given cell” and includes
splice variants, and noncoding transcripts. Gene expression
microarrays were developed to address how in a given pop-
ulation of cells a profile of the transcriptome can be identi-
fied. A significant number of studies have used gene microar-
ray studies to examine the gene expression signature of
mesothelioma. These can be subdivided into two types of
study, those which involve analysis of mesothelioma derived
cell lines, and those which involve mesothelioma patient
samples. In the following sections we will describe the
current knowledge obtained from both types of study.
Gene Expression Microarray Studies Utilizing
Cell Lines
Several gene expression profiling studies have been
carried out on mesothelioma derived cell lines. Rihn et al.34
used both a cDNA microarray comprising 6969 probes and a
high density filter array to compare gene expression profiles
between a control SV40 transformed mesothelial cell line
(Met-5A) and a mesothelioma derived cell line (MSTO-
211H). The analysis identified genes which were up-regu-
lated in MSTO-211H when compared with Met-5A. The
categories of genes which were up-regulated included those
involved with macromolecule stability and metabolism (e.g.,
heat shock proteins, HSP60, HSP90; Fatty Acid-Binding
Protein 5, FABP5), adhesion (examples include integrin 3,
ITGA3, integrin 4, ITGA4, and integrin 6, ITGA6), inva-
sion (plasminogen activator inhibitor, type 2, PAI-2), cell
cycle regulation and growth (e.g., cyclin H, CCNH; cyclin
dependent kinase 7, cdk-7; V-KI-RAS2 Kirsten Rat Sarcoma
Viral Oncogene Homolog, Ki-Ras; and the MYC oncogene,
c-MYC), and oxidative stress response (e.g., superoxide dis-
mutase 1, SOD1). Overall these differences indicate that these
pathways may be important for the pathogenesis of mesothe-
lial cell transformation, and the well documented chemo- and
radio-resistance of mesothelioma.
In an array based study of four malignant mesothelioma
cell lines established from primary tumors (M14K, M24K,
M25K, and M38K), comparison was made with two refer-
ence primary mesothelial cell cultures derived from the pleu-
ral fluid of noncancer male patients. Up-regulated genes in
the malignant mesothelioma cell lines were found to be
involved with determination of cell fate (e.g., Jagged 1,
JAG1), cell cycle (including cyclin D1, CCND1; cyclin D3,
CCND3; and CDK phosphatase, CDC25B), cell growth (e.g.,
Nerve Growth Factor 2, NgF2; Fibroblast growth factor
3, FGF3), adhesion (e.g., cell adhesion molecule 1, L1CAM),
cell motility (e.g., integrin 3, ITG3), cell invasion (e.g.,
keratinocyte growth factor, FGF-7) and DNA damage re-
sponse (Inhibitor of Growth 1, ING1/p33ING1), indicating
that these genes may be important for MPM tumor invasion.35
Using a cDNA microarray approach to identify genes
which were overexpressed in a panel of seven mesothelioma
cell lines, Kim et al.36 identified a regulator of microtubule
dynamics, stathmin, as being a gene which is frequently
up-regulated in these cell lines, and subsequently demon-
strated its overexpression in primary malignant mesothelioma
samples. Aberrant microtubule dynamics caused by the over-
expression of stathmin may play important roles in the
pathogenesis of mesothelioma.
Effects of Fibers/Asbestos on Gene Expression
Profiles in Mesothelioma Derived Cell Lines
As asbestos exposure has been clearly implicated in the
development of MPM, several studies have attempted to
document the changes in gene expression in mesothelial and
mesothelioma cell lines exposed to asbestos fibers. In a study
of rat pleural mesothelial cells exposed to asbestos, genes that
were up-regulated were found to mostly function in cellular
transport, but protein kinases and proto-oncogenes such as
hepatocyte growth factor receptor (c-Met), c-myc and fos-
related antigen-1 (Fra-1), were also identified as being sig-
nificantly up-regulated. Fra-1 expression has been previously
shown to be a critical to the morphologic transformation of
mesothelial cells.37
A similar more recent study by Nymark et al., exam-
ined the response of Met5A to crocidolite asbestos exposure.
Using Gene Ontology analysis, the authors identified several
important Gene Ontology biologic processes for which gene
expression was either up- or down-regulated following expo-
sure to asbestos fibers. These included the down-regulation of
genes associated with cytoskeletal anchoring, while genes
involved with nucleosome assembly, regulation of transla-
tional initiation, and the regulation of cell survival were
found to be up-regulated.38 The pathways identified by Ny-
mark et al., may therefore be also important pathways acti-
vated by asbestos in the pleura, and as such may play
important roles in the progression to MPM.
In a microarray study on Met-5A mesothelioma cells
exposed to crocidolite, erionite, and the proinflammatory
cytokines IL-1Beta and TNF-alpha, Swain et al.,39,40 demon-
strated that the chemokine superfamily including the chemo-
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kines CXCL1 (GRO), CXCL10, IL-8, and CCL20 were
significantly up-regulated following exposure to these condi-
tions. Independent confirmation for the up-regulation of
CXCL10 and IL-8 has been observed in mesothelioma cell
lines,41–43 although one study observed up-regulation of
IL-10 shortly after exposure to crocidolite, but which was
subsequently lost over long-term exposure.38
Chemokines are chemoattractant cytokines which func-
tion to regulate the trafficking and activation of leukocytes
and other cell types under a variety of inflammatory and
noninflammatory conditions. Increasingly, studies have
shown that chemokines play an important role in several
aspects of tumor progression.44,45 Tumor cells express func-
tional chemokine receptors, which can sustain proliferation,
and survival and promote organ-specific localization of dis-
tant metastases. Furthermore, chemokine expression in tu-
mors is also associated with hindering antitumor immune
responses through regulation of leukocyte infiltration and
thereby favoring the establishment of immune escape mech-
anisms in the tumors.46 In a seminal study, elevated expres-
sion of IL-8 was observed in pleural fluid samples from
mesothelioma patients, and immunohistochemistry of pleural
biopsy specimens showed that IL-8 was localized to the
malignant mesothelioma cells, but not to other types of
malignant metastatic deposits. In vitro mesothelioma cell
lines were subsequently shown to constitutively express IL-8
mRNA while normal resting human mesothelial cells did
not.47 While IL-8 is known to have angiogenic activity,48 it
has also been shown to have growth-promoting activity in
mesothelioma and inhibition of IL-8 activity in a nude mouse
model of mesothelioma resulted in a reduction of MPM
progression.49,50 Indeed, in lung and colon cancer cells Toll-
Like Receptor 4 (TLR-4) signaling has been shown to pro-
mote immune escape by inducing both IL-8 and CCL20.51,52
This observation coupled to the data showing that Met-5A
MPM cells stimulated with TNF- or IL-1 overexpress
these chemokines provides a potential link between chronic
inflammation and tumor immune escape in mesothelioma,
and indicate that IL-8 may represent a therapeutic target in
the treatment of mesothelioma.
The up-regulation of the chemokine superfamily in
mesothelioma cells exposed to fibers therefore represents a
critical pathway in malignant mesothelioma pathogenesis,
linking inflammation, angiogenesis, and tumor immune es-
cape.
Changes in Microarray Gene Expression
Profiles in Mesothelioma Cells Undergoing
Differentiation
Malignant pleural mesothelioma is an aggressive tu-
mor, characterized by a variable differentiation pattern. Clin-
ical outcome in patients relies mainly on predictions based on
the morphologic phenotype of the tumor. In an attempt to
study MPM tumor differentiation, Dobra and coworkers used
an array approach to examine an in vitro model of MPM
differentiation, by studying the gene expression profiles of
two well established MPM cell sublines. The authors com-
pared the gene expression signature of the epitheliod
STAV-AB MPM cell line to that of the Fibroblastoid STAV-
FCS cell line. Two expression pattern signatures (comprising
a total of 102 up-regulated genes) were identified which could
distinguish between epithelial and sarcomatoid subtypes. Sar-
comatoid tumors contained elevated levels of growth factor
receptors and associated binding proteins (examples include
Platelet-Derived Growth Factor Receptor Beta, PDGFR;
Fibroblast Growth Factor Receptor 1, FGFR1; Transforming
Growth Factor beta 1, TGF1), whereas epithelial mesothe-
lioma cells were found to have overrepresentation of tumor
promoting factors involved with differentiation (examples
include Keratin 5, KRT5; Bone morphogenetic protein 4,
BMP4), metabolism (Phosphatidylinositolglycan class F,
PIGF; Proteasome activator subunit 2, PSME2), and regula-
tion of apoptosis (Immediate early response 3, IER3; Nuclear
factor of kappa light polypeptide gene enhancer in B-cell
inhibitor, alpha, NFKBIA).53 Overall, the expression profile
for the epitheliod cell line was that expected for a more
differentiated tumor. In MPM epitheliod histology is associ-
ated with a lower malignant potential and better responses to
therapy. The fibroblast-like cell line had a profile more
commonly associated with growth factors and genes that may
contribute to the particularly unfavorable prognosis of sarco-
matoid tumors.
In a similar study Hida et al., established two new
MPM cell lines, Y-MESO-8A (epithelial-like morphology)
and Y-MESO-8D (spindle-like morphology) from a patient
with biphasic (sarcomatoid/epithelial) features. Using mi-
croarray gene expression based profiling to compare between
these two cell lines, the authors found 43 genes which had
greater than fivefold differences between the two cell lines.
Genes involved with cell structural activity (e.g., Filaggrin,
FLG; Microfibril-associated glycoprotein-2, MAGP2) or cell
adhesion (e.g., Tissue inhibitor of metalloproteinase 3,
TIMP3) were overexpressed in the epithelial (Y-MESO-8A)
cell line over the spindle (Y-MESO-8D) cell line, but no
differences in the expression of major cancer associated
genes were found between the two cell lines.43 In MPM, it is
generally considered that the sarcomatoid (spindle-like) sub-
type is a more aggressive form than the epitheliod subtype.43
In the same study, 15 genes were identified which had greater
than fivefold up-regulated expression in the sarcomatoid
subtype (Y-MESO-8D) compared with the epithelial like
subtype (Y-MESO-8A) were identified.43 These included the
proinflammatory cytokines interleukin-1 (IL-1), and inter-
leukin 8 (IL-8), and several genes involved with cell growth
and communication (including Vascular cell adhesion mole-
cule 1, VCAM1; and Solute carrier family 21 (organic anion
transporter), member 9, SLC21A9). Indeed in a small study of
16 cases, immunohistochemical analysis demonstrated
VCAM-1 expression in 14 of 16 cases of mesothelioma.54 In
a lung epithelial cell culture model IL-1alpha has been shown
to be able to regulate expression of VCAM-1,55 and in an
early study in melanoma, cells overexpressing IL-1alpha
when injected into mice, increased the expression of
VCAM-1 on lung microvascular endothelial cells.56
While the function of SLC21A9 has been proposed to
be involved with the uptake of steroid hormones and their
conjugates, drugs, and numerous anionic endogenous sub-
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strates,57 SLC21A9 also shares 42.8% amino acid sequence
identity with a rat prostaglandin transporter.58 As prostaglan-
dins are linked to both inflammation and cancer, the data
obtained from the array study supports the idea that in spindle
cells there is a more proinflammatory environment resulting
in elevated expression of adhesion molecules such as
VCAM1, and may therefore explain to some degree why in
the spindle subtype of MPM is associated with a more
aggressive phenotype.
Gene Expression Profiling of Primary
Mesothelioma to Identify Predictive or
Prognostic Biomarkers
With the advent of gene expression profiling frequent
use of arrays has been carried out on MPM patient material,
in attempts to identify profiles which may be predictive
(predictive of disease presence), prognostic (predictive of
long term patient prognosis) and/or treatment response (pre-
dictive of personalized therapy).
Bueno and coworkers initially used arrays to distin-
guish MPM from lung cancer through differential gene ra-
tios.59 A subsequent follow-up study identified 46 candidate
prognostic genes for MPM and defined a four gene set whose
expression ratios could predict treatment related outcome.60
More recently, the authors validated this signature in a further
study of MPM, and identified seven new potential prognostic
markers.61 In a similar experiment Pass et al.,62 using neural
network classification, identified a 27 gene signature for
MPM which was both prognostic for patient survival and
predictive for disease progression. Using Onto-Express anal-
ysis, a tool which can automatically translate lists of differ-
entially regulated genes into functional profiles for biochem-
ical function, biologic process, cellular role, cellular
component, molecular function and chromosome location,63
the authors identified the following biologic processes im-
pacted by their 27 gene signature: cell proliferation, lipid
metabolism, positive regulation of cell proliferation, regula-
tion of transcription from Pol II promoters, pathogenesis, cell
cycle arrest, negative regulation of cell proliferation, inflam-
matory responses, induction of apoptosis by extracellular
signals, DNA damage response through activation of p53,
and RNA processing.62
A study from the group of Marc Ladanyi on MPM also
identified a 29 gene signature set which had prognostic value,
and compared their results to those of Bueno and Pass. Their
conclusion was that gene expression profiling had an upper
limit of around 65% predictive, below the level of clinical
usefulness.64 Nevertheless, the authors identified gene Aurora
Kinase B, AURKB, which was overexpressed in both sarco-
matoid and epithelial MPMs. However, the overexpression
was only associated with unfavorable outcome in the epithe-
lial subtype.64 Using Ingenuity Pathway Analysis software,
the authors linked 11 of their 29 gene prognostic classifier set
into a single network of genes associated with cell cycle
control and mitosis, cell death and cancer.
Glinsky et al.65 have identified an 11 gene stem cell like
signature driven by the Leukemia Viral Oncogene BMI-1,
which has prognostic power in MPM, and 10 other distinct
types of cancer. This 11 gene signature was associated with
(a) highly malignant cancers, (b) propensity toward meta-
static dissemination, and (c) with predicting a high probabil-
ity of therapy failure in these cancers. These results may
consequently have general application in the diagnosis and
management of cancer, and may prove to be an important
breakthrough in understanding cancer biology. One caveat in
relation to the results obtained for MPM, is that the number
of samples involved was small (n  17), and so independent
validation of these results in a large prospective study are
warranted.
Gene Expression Profiling Studies to Identify
Mesothelioma Biomarkers/Pathways
In a study examining 10 MPM cell lines and four
primary tumors Kratzke and coworkers66 used gene expres-
sion profiling to identify a subset of 180 genes whose differ-
ential expression had the capability to distinguish between
MPM subtypes. This study identified matriptase (ST14) as a
gene which differentiated the epithelial subtype from sarco-
matoid or biphasic MPMs, and identified insulin-like growth
factor binding protein 5 (IGFBP-5), as a gene significantly
down-regulated in MPM.
Other groups have attempted to use gene expression
microarrays to identify potential MPM biomarkers, or impor-
tant pathways which may be important for MPM pathogen-
esis. One early study by Albeda and coworkers67 revealed
that pathways involved with glucose metabolism, protein
translation and cytoskeletal remodelling were frequently al-
tered in MPM. Using a combination of laser capture micro-
dissection and gene expression arrays Rihn and coworkers68
identified 14 genes. Of these eight were up-regulated (com-
plement factor b, BF; ferritin light polypeptide, FTL; Insulin-
like growth factor binding protein 7, IGFBP7; retinoic acid
receptor responder 1 RARRES1; retinoic acid receptor re-
sponder 2, RARRES2, retinol-binding protein 1, RBP1; sper-
midine/spermine N1-acetyltransferase, SAT; Thioredoxin,
TXN), while six were down-regulated (arachidonate 5-lipoxy-
genase-activating protein, ALOX5AP; chloride channel nucle-
otide-sensitive 1A, CLNS1A; eukaryotic translation initiation
factor 4A, isoform 2 EIF4A2; ETS-Domain Protein 3, ELK3;
REQUIEM, Apoptois Response Zinc Finger Gene, REQ; and
synaptophysin-like protein, SYPL) in microdissected MPM
cells compared with microdissected mesothelial pleural cells.
Mohr et al., identified 700 genes in two primary epi-
thelial MPM tumors which were differentially expressed
compared with a pleural cell line (MET-5A). Two major
categories of genes identified were found to be altered in
MPM. The first, (cell protection and resistance), included
subcategories involving nucleic acid integrity and repair;
protein stability and maintenance, oxidative stress and drug
metabolism. The second category (Tumor invasiveness), in-
cluded subcategories such as adhesion, extra cellular matrix
components, and genes involved with metastatic potential.69
In a study examining the gene expression profiles of 17
mesothelioma patients with different overall survival times,
Gordon et al.,60 defined 46 potential prognostic molecular
markers which could distinguish two outcome-related groups
of patients. Taking the top four genes which were the most
statistically significantly overexpressed in each outcome
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group, by examining the various gene expression ratio permu-
tations they narrowed this set down to four gene pair ratios
whose expression ratios could predict outcome. The genes iden-
tified using this strategy were Cordon-bleu protein-like 1,
COBL-like 1/KIAA0977; cytosolic thyroid hormone binding pro-
tein, CTHBP, Guanosine diphosphate-dissociation inhibitor 1,
GDIA1; and an EST similar to the L6 tumor antigen),60 and this
prognostic test was subsequently validated in a follow-up
study.61
Using a different microarray platform and 39 different
MPM samples Gordon et al., identified seven new candidate
prognostic markers, whose expression ratios could stratify
patients with poor outcome from those with better outcome.
The identified genes were CD9 antigen, CD9; Discs, large
(Drosophila homologue) 5 DLG5; complement component 3,
C3, and one EST; DKFZp586J2118 with unknown function,
small cell lung cancer carcinoma cluster four antigen, CD24;
KIAA1199; and thrombomodulin, THBD in MPM.61
Bueno and coworkers70 also used microarray gene
expression profiles to identify 328 genes significantly up-
regulated in MPM tumors relative to normal tissues. Unsu-
pervised clustering of these genes identified two potential
subclasses of mesothelioma- that correlated loosely with
tumor histology. Further analysis of this clustering identified
sets of genes which could distinguish between multiple tumor
subclasses, normal and tumor tissues, and tumors with dif-
ferent morphologies. Three novel up-regulated candidate onco-
genes (nucleotide-diphosphate kinase 2, NME2; CREBBP/
EP3000 inhibitory protein 1, CRI1; Platelet-derived growth
factor C, PDGFC) and one novel down-regulated candidate
tumor suppressor gene (Gelsolin, GSN) were identified in this
analysis.70
Knuutila and coworkers42 examined the expression of
588 genes associated with cancer in MPM, and identified 25
genes which were deregulated. Examples of the genes iden-
tified included down-regulation of the growth factor (Basic
Fibroblast Growth Factor, BFGF), elevated expression of the
chemokines (CXCL10, and CXCL2) and both elevated and
reduced expression of genes involved with cell adhesion.
Ezrin was found to be reduced while Integrin 4 levels were
elevated. Genes involved with tumor invasion (Matrix met-
alloproteinase 9, MMP9) were found to be elevated, and also
proto-oncogenes (colony-stimulating factor-1 receptor, CSF1R).
A multidrug resistance gene (Semaphorin 3C, SEMA3C), was
also found to be overexpressed in these samples. Overexpression
of this gene in recurrent lung carcinomas and in a cisplatin
resistant MPM line is associated with drug resistance.71
Another potential therapeutic pathway for MPM was
discovered using a custom array designed to examine the Wnt
signaling pathway which identified Wnt2 as being a potential
new biomarker for mesothelioma.72
Inhibitor of apoptosis-1 (IAP-1), was previously been
shown to be a novel up-regulated gene in MPM using
differential display.73 In a follow-up study Gordon and co-
workers used gene expression profiling to examine the ex-
pression of IAP family members in MPM, and demonstrated
that several family members had prognostic value. IAP-1 and
Baculoviral IAP Repeat-Containing Protein 5 (BIRC5, also
known as Survivin) expression correlated with a relatively
shorter patient survival, while Inhibitor of apoptosis, X-
linked, (XIAP) and Baculoviral IAP Repeat-Containing Pro-
tein 7 (BIRC7, also known as livin) were associated with
longer patient survival.74
Gene Expression Profiling to Examine
Response to Therapy in Mesothelioma
Gene expression profiling has also been used to exam-
ine the response to therapeutic drugs in mesotheliomas. In a
phase I clinical trial for the effects of Decitabine (a DNA
methyltransferase inhibitor) in patients with cancers of the
lung, esophagus or pleura, David Schrump and coworkers
examined tumor biopsies pre and posttreatment for target
genes (NY-ESO-1, MAGE-3, and p16), known to be down-
regulated by methylation. They demonstrated robust alter-
ations to their expression in 8 of 22 individuals which
completed treatment. Subsequently, using laser capture mi-
crodissection of tumor cells isolated from one MPM patient
before and after decitabine treatment, they observed that
prolonged low-level decitabine exposure could modulate
global gene expression patterns (75 genes induced, 324 genes
repressed twofold by decitabine) in this patient.75 Of these
pathways, members of the Notch signaling, Heterotrimeric
G-protein signaling (Gq alpha and Go alpha mediated & Gi
alpha and Gs alpha mediated pathway), JAK/STAT signaling,
Interferon-gamma signaling, and chemokine and cytokine
signaling inflammatory pathways were identified as having
originally been up-regulated or overexpressed in the tumors
but subsequently down-regulated following decitabine treat-
ment (75supplementary information Table 1).
Using Arrays to Identify Cytogenetic
Alterations in Mesothelioma
Standard techniques for the identification of chromo-
somal abnormalities (Karyotyping, CGH) have confirmed
that there are frequent complex chromosomal imbalances
TABLE 1. Predictive Genes in MPM for Which Alternative
Validation Exists
Gene Original Array Study Confirmation Array Study
BIRC1 64 74,151
CRIP1 62 70
HEG1 62 70
IGFBP-5 62 42,70a
MYC 62 70
PLXNA3 64 42
RARRES1 64 68,70
SEMA3A 60 70
SPOCK2 62 67,70
WT1 64 70
a Caveat–IGFBP-5 was found to be commonly down-regulated by Hoang CD,
D’Cunha J, Kratzke MG, et al. Gene expression profiling identifies matriptase overex-
pression in malignant mesothelioma. Chest 2004;125:1843–1852.
BIRC1, Baculoviral IAP repeat-containing protein 1; CRIP1, cysteine-rich intestinal
protein 1; HEG1, heg homolog 1 (zebrafish); IGFBP-5, insulin-like growth factor binding
protein 5; MYC, v-myc avian myelocytomatosis viral oncogene homolog; PLXNA3, plexin
A3; RARRES1, retinoic acid receptor responder 1; SEMA3A, Semaphorin 3A; SPOCK2,
sparc/osteonectin, cwcv, and kazal-like domains proteoglycan 2; WT1, WT1 gene.
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associated with MPM.76 These cytogenetic changes, how-
ever, are limited in relation to their mapping resolution. Array
technology has the potential to more precisely demarcate
cytogenetic abnormalities in MPM, with the development of
both CGH-Arrays and SNP-based mapping arrays. Several
recent reports have used these technologies in the study of
MPM, and the main findings have been summarized in
Table 2.
One of the limitations of standard cytogenetic methods
is that resolution, in relation to the precise location of the
cytogenetic changes is poor. Currently, standard CGH can
provide only limited resolution at the 5 to 10 Mb level for the
detection of copy number losses and gains, and at 2Mb for
amplifications. Array-CGH has overcome some of these lim-
itations bringing resolution down to approximately 0.7 Mb.
High density oligonucleotide microarrays based on SNP have
recently been shown to identify both copy number alterations
and loss of heterozygosity at very high resolution.77–79 Using
this approach Testa and coworkers examined loss of chromo-
some 9p21 (a region which contains CDKN2A also known as
TABLE 2. Most Frequent Copy Number Alterations Found in Mesothelioma of Chromosomal Losses and Gains of Malignant
Mesotheliomas as Detected by CGH, Array-CGH or SNP-Genotyping
Standard Cytogenetics (Cytogenetics,
FISH, LOH) CGH Array-CGH
SNP-
Array
Potential
Important Genes
Implicated in
MPM
Gains
1, 3, 5, 6, 7, 11, 17, 20 1p31.3-pter, 1q (incl. 1q23, 1q32,)
4p15.3-pter, 5p, 5q31-qter, 6p, 7,
7p14-p15, 7pter-q11.2, 7q22,
7q32-q33, 8pcen-p12, 8q, 8q22–
23, 8q24-qter, 10q25.1-qter,
11qcen-q22, 12, 13q13.3-q14.2,
14q24-qter, 15q22-qter, 17q22-
q24, 20, 22, 22q trisomy 19,
trisomy 22q
1p32.1, 1q, 2p (incl. 2p11.2-q11.2,
2p14.3-p13.3, 2p23, 2p25.1,
2p23), 2q32.1, 3q11-q27, 4p12,
4p13, 4p14, 4p15.1, 4p16.3, 5p
(incl. 5p15.33-p13.1), 7p (incl.
7p15.1, 7p22.3-p22.2), 8q24,
8q24.3, 9p13.3, 9q, 10q24.1-
q24.2, 10q26.12-q26.13,
10q26.13, 11p15.5-p15.4,
11p15.4, 11q12.1-q13.1,
11q22.1, 11q22.2-q22.1,
12p13.2-p13.1, 12q13.3,
15q11.2-q12, 17q (incl.
17q21.32-qter, 17q21.31,
17q21.33), 19p13.12, 20p,
20p11.21-q11.21, 20q11.22-
q11.23, 20q13.12, 20q13.13,
21q11.2, Xp22.33, Xq28
1p32.1 (JUN) 11q13
(Fra-1) 11q22
(YAP1, CHK1)
Losses
1p21-p22, 3p21, 3p21.3, 4p, 4p15, 4q, 4q25-
q34, 6q (incl. 6q14-q25, 6q15-q21, 9p
(incl. 9p13, 9p21, 9p22, 9p21-p22),
11p11-p13, 13q, 13q 13.2-q14.2, 14q,
15q15, 17p13, 22, 22q12
1p, 1p11-p22/p31, 1p21, 3p, 3p21,
4p (incl. 4p11-p13/p15, 4p12-
p13), 4q31.1-qter, 4q31-q22, 5q,
6q (incl. 6q11-q21, 6q12-q14,
6q14, 6q22-q24), 7q, 8p (incl.
8p12-p21, 8p21-pter), 9p (incl.
9p13-p21, 9p21, 9p21-pter),
10p13-pter, 13 (incl. 13q12-q14,
13q13-q14, 13q21.1-q22), 14,
14q (incl.14q12-q24, 14q24.2-
qter), 15, 15q (incl. 15q11.1-q15,
15q11.1-q21, 15q11.2–13,
15q12–14; 15q14-q15), 17p,
17p12-pter, 22, 22q, Y
1p (incl. 1p13.1p12, 1p31.1,
1p31.1-p13.2, 1p36.33, 1p36.1,
1p21.3), 1q34-qter, 3p (incl.
3p22.1-p14.2, 3p21.2–21.3),
3q27-qter, 3q27.3-q28, 4, 4q
(incl. 4q22, 4q34.3-q35.1, 4q34-
qter), 6p11.2-q12, 6q (incl.
6q12-q16.3, 6q22.1, 6q22.31,
6q25, 6q26), 7q35, 9p (incl.
9p21.1, 9p21.2, 9p21.3, 9p24.3-
p21.2), 10p (incl. 10pter-p12.1,
10pter-p11.22, 10p11.22,
10p11.21, 10p15.3), 10q26.2–
10q26.3, 11q, 11q25, 13, 13q
(incl. 13cen-q14.12, 13q33.2),
14, 14 q (incl. 14q22.1-qter,
14q32.13), 15q15.1-q21.1, 16q,
18, 18q, 22q (incl. 22q11.1-
q11.23, 22q11.23-q13.33,
22q12.2, 22q12.2-q12.3,
22q12.3, 22qcen-q12.3),
Xq25, Y
9p21 3p21 (RASSF1A,
CTNNB1)
9p21
(CDKN2A/ARF,
p16INK4a)
17p13 (TP53)
22 (NF2/Merlin)
Identified from Pubmed using the following search expressions: mesothelioma CGH, mesothelioma array-CGH mesothelioma array-based comparative genomic
hybridization mesothelioma SNP array, mesothelioma cytogenetics.
Additional information came from http://www.mesotheliomainfected.com/cytogenetics-of-malignant-mesothelioma.html.
LOH, loss of heterozygosity; FISH, fluorescence in situ hybridization; CGH, comparative genomic hybridization arrays; SNP, single nucleotide polymorphism; JUN, v-jun avian
sarcoma virus 17 oncogene homolog; FRA1, fos-related antigen 1; YAP1, yes-associated protein 1, 65-kd; CHK1, cell cycle checkpoint kinase; RASSF1A, ras association domain
family protein 1; CTNNB1, catenin, beta-1; CDKN2A/ARF, cyclin-dependent kinase inhibitor 2a (arf included); TP53, tumor protein p53; NF2 (Merlin), neurofibromin 2.
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INK4A/ARF) in 4 MPM cell lines and precisely demarcated
two different, but overlapping deletions. All of the deletions
in the cell lines encompassed the CDKN2A and CDKN2B
loci. The four MPM cells all exhibited a similar deletion
pattern; that is, each showed both a pronounced loss of signal
for multiple contiguous markers in 9p21 surrounded by a
larger region with a lesser loss of signal. This is considered to
be indicative of a homozygous deletion embedded within a
heterozygous deletion.80 Using CGH based arrays Szlosarek
et al. examined seven mesothelioma cell lines for loss of
9q34, a region which contains a gene down-regulated in
MPM, argininosuccinate synthetase. The authors found no
loss of heterozygosity in the cells, and subsequently went on
to show that the down-regulation of this gene was through
epigenetic inactivation.81 Sekido and coworkers used genome
wide array based CGH on 17 primary tumors and nine cell
lines confirming the frequent losses and gains observed
through standard cytogenetic or CGH methods, but also
identifying new regions of interest including gains of 8q24
and loss of 13q33.2. In addition, the authors identified a high
copy number gain of chromosomal region 1p32 (a region
which includes the proto-oncogene JUN.82
The effects of DNA copy-number changes on MPM
gene expression profiles has recently been determined using
a combination of array-CGH and array gene expression
profiling. Using two cytogenetically unstable MPM cell lines
(PMR-MM2 and PMR-MM7) as their in vitro model, Looi-
jenga and coworkers studied the impact of DNA copy number
changes on the cells gene expression profiles over time. DNA
losses and gains were identified using microarray-based ar-
ray-CGH, and coupled with minimal overlapping analysis
this led to the identification of several common unbalanced
genomic regions at early passages with 27 regions of DNA
gain and 14 regions of DNA loss. Many of these loses and
gains correlate well with previously published cytogenetic
studies. Following long term culture of PMR-MM7, gains of
chromosomal regions 1p34.2-p34.1, 3p25.1, 16q23.2-q23.3,
and 19p13.13 were observed, while loss of 7p13 occurred.
Subsequently the authors analyzed the gene expression pro-
file of one of these cell lines PMR-MM7 after early and late
passages, and correlated the differentially expressed genes
with the copy-number changes identified using the array-
CGH. From this analysis the authors demonstrate that pro-
longed culture of this unstable MPM cell line led to the
acquisition of additional chromosomal copy-number changes
associated with dysregulation of genes involved in cell adhe-
sion, regulation of mitotic cell cycle, signal transduction,
carbohydrate metabolism, motor activity, glycosaminoglycan
biosynthesis, protein binding activity, lipid transport, ATP
synthesis, and methyltransferase activity.83
Using array-CGH on a series of 26 well characterized
MPM samples, Knuutila and coworkers found that gene
losses were predominant in MPM. The most frequent losses
observed occurred in 1p31.1 3 p13.2, 3p22.1 3 p14.2,
6q22.1, 9p21.3, 13cen 3 q14.12, 14q22.1 3 qter, and
22qcen 3 q12.3. Novel findings included gains of 9p13.3,
7p22.33 p22.2, 12q13.3, and 17q21.323 qter.38 The most
frequent region of loss 9p21.3 (occurring in 17 of the 26
MPM), contains the loci for CDKN2A and CDKN2B, two
important genes known to be frequently lost in MPM.
Mesothelioma Tissue Microarrays (TMAs)
Tissue microarrays (TMAs) represent a high-through-
put method for the investigation of biomarkers in multiple
tissue specimens at once. Composed of arrays of core biop-
sies obtained from paraffin-embedded tissues, up to 1000
tissue samples can be analyzed in a single experiment using
either immunohistochemistry or in situ hybridization. TMAs
play a central role in translational research, facilitating the
analysis of molecules that have potential roles in the diagno-
sis, prognosis, and prediction of response to therapy.84–87 The
advantages of TMAs include conservation of rare clinical
resources, experimental uniformity/standardization, decreased
assay volume, and high-throughput.84,88 This is critically
important for tumors such as mesothelioma, and allows the
use of stored archival tissue.
One of the most frequent concerns surrounding TMAs,
has been whether the small size of the tissue cores used can
be representative of an entire tumor. Many studies have
sought to address this, and have achieved high concordance.
Additional studies to identify the optimal number of cores
required for concordance and have found that only two-three
such cores are required per sample.85,86 There are some
drawbacks to TMAs. The first is the limitation imposed by
availability of validated antibodies suitable for use in immu-
nohistochemistry. Additionally, the issue of loss of antige-
nicity in samples must also be considered, although this
would appear to be related to how samples or slides are stored
rather than in the construction of TMAs.88 One of the biggest
hindrances currently with the use of TMAs in a high-through-
put setting has been TMA reading and analysis.85,86 However,
as with all such technology sophisticated hardware and soft-
ware tools are emerging to alleviate this.
Several recent studies on mesothelioma have used
TMA technology to study either individual protein or protein
signatures in mesothelioma. Kettunen et al. identified an 11
gene signature which could differentiate between the various
mesothelioma subtypes. Using TMA, the authors studied five
members of this signature in more detail, and found that three
of the identified genes (P-cadherin, neural cell adhesion
molecule L1/L1CAM, and integrin 4/ITGB4) were signifi-
cantly elevated in the epithelial subtype.42 In a similar type of
analysis Gordon et al. identified gene signatures which could
be loosely correlated with mesothelioma subsets on the basis
of morphology. They subsequently studied the expression of
three candidate oncogenes (Nonmetastatic Cells 2/NME2,
CREBBP/EP300 Inhibitory Protein 1/CRI1, and Platelet De-
rived Growth Factor-C/PDGFC), and one candidate tumor
suppressor (Gelsolin/GSN) using TMA. Using this approach,
the authors found that two of the examined candidates CRI1
and NME2 had significantly elevated expression in tumor
cells, with no detectable expression of these proteins in
normal pleura or stromal cells within the tumors.70 In a
follow-up study Gordon et al.89 studied expression of the
Inhibitor of Apoptosis (IAPs) family and demonstrated abun-
dant expression of all IAPs in MPM tumors, and could be
associated with MPM survival. Pass et al., used an MPM
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TMA derived from 38 individuals to examine osteopontin
expression. Positive staining for osteopontin was observed
for 36 of the 38 individuals,90 and subsequently serum levels
of osteopontin were examined and found to have prognostic
significance in the detection of mesothelioma (discussed in
more detail in the following section). The c-MET proto-
oncogene has been shown to be highly expressed in MPM
both by standard assays and gene expression profiles.70 More
recently a study used TMA to examine c-MET in more detail,
and has confirmed that this gene has elevated expression in
MPM and no staining in normal pleura.91 Szlosarek et al.81
identified Argininosuccinate Synthetase/AS (a key regulator
of the arginine biosynthesis pathway) as a gene which is
frequently down-regulated in MPM, and used a TMA array to
confirm that levels of AS are absent in 63% of MPM patients
regardless of subtype, although predictive or prognostic val-
ues were associated with this decrease.
In a recent study for alterations of expression of Phos-
phatase and Tenisn Homolog, Weder and coworkers used a
341 MPM TMA. From their analysis a significantly longer
median survival time occurred in patients expressing Phos-
phatase and Tenisn Homolog independently of histologic
subtype.92
Array Technology to Study Mesothelioma
Serum/Proteomics
Proteomics, or the ability to study all of the proteins
encoded by the genome represents a branch of research with
significant potential within diagnostic, screening or prognos-
tic settings in cancer management. Within oncology, pro-
teomics may prove to have significant benefit in the areas
related to biomarker discovery, treatment, and early detection
through serum screening or tissue sample analysis, and to
develop targeted pharmacoproteomic therapies.93
Oncoproteomics has been coined to describe the idea
that certain protein signatures or patterns can be associated
with a particular malignancy, which if combined with clinical
correlations could allow the prediction of disease progression
and perhaps improved therapeutic modalities.94 In this regard,
antibody arrays allow the simultaneous measurement of many
proteins in experimental samples, and show great promise in
the development of high-throughput strategies for clinical
proteomics in the identification of cancer biomarkers, diag-
nosis, and management of cancer.95–97 Tumor-associated an-
tigen arrays (TAAs) are also emerging as a novel approach to
serological diagnosis of cancer. TAA arrays comprising sev-
eral antigens against cancer-associated autoantibodies greatly
increase the diagnostic utility of TAAs in the diagnosis of
cancer from sera.98
As this area of research is still in its infancy, relatively
few large scale proteomic studies on mesothelioma have been
described. The most comprehensive study involved the anal-
ysis of exosomes secreted from primary mesothelioma cell
lines derived from patients.99 Of the proteins identified,
several were involved with antigen presentation, signal trans-
duction, migration and adhesion. A follow-up study on exo-
somes isolated from the pleural fluid of mesothelioma pa-
tients identified proteins involved with blood coagulation
(Complement factors & Fibrinogen), various immunoglobu-
lins, and Cytoplasmic linker protein 2 (KIAA0291), a protein
whose function is proposed to mediate the interaction be-
tween specific membranous organelles and microtubules.100
Recently, using an array based technology, the expres-
sion profiles of 80 cytokines and chemokines were examined
in mesothelioma cell lines and the pleural fluids obtained
from the original patients from which the mesothelioma cell
lines were derived.41 Several important proteins involved
with immune suppression, angiogenesis, and plasma extrav-
asation could be detected in both cell line supernatant and
primary pleural effusions including angiogenin, vascular en-
dothelial growth factor, transforming growth factor-, and
epithelial neutrophil-activating protein-78. From the same
study, immunohistological staining demonstrated heavy infil-
tration by many immune effector cells, and significant
amounts of Foxp3  CD4  CD25  regulatory T-cells,
which when depleted in a murine mesothelial model in-
creased long term survival.41
A significant number of studies have focused on devel-
oping serum based assays for the diagnosis of mesothelioma.
The best characterized of these is the serum marker mesothe-
lin. Soluble mesothelin (SMRP) is a 40 kDa glycoprotein
cleavage product of the membrane bound form of mesothelin,
which is released into plasma serum by the activities of
furin-like proteases.101 The first report that this soluble pro-
tein could be a potential useful biomarker in the detection of
mesothelioma came from the laboratory of Bruce Robinson,
where 84% (37/44) patients had elevated SMRP levels.102
This sensitivity was confirmed in a follow-up study which
also demonstrated 95% specificity for the enzyme-linked
immunosorbent assay (ELISA) based assay.103 Independent
studies have continued to confirm the sensitivity of mesothe-
lin.104–107 However, a recent study has raised the issue of high
false positive rates in a study comparing healthy individuals
to healthy individuals exposed to asbestos.108
The reliability and sensitivity of the mesothelin assay
has led to the development and marketing of ELISA based
assays for the detection of SMRP.78,109–111 Most recently, a
phase I clinical trial targeting mesothelin with a recombinant
mesothelin immunotoxin (SS1P) has been completed. Of the
33 evaluable patients treated, 4 had minor responses, 19 had
stable disease, and 10 had progressive disease. A phase II
clinical trial is currently being planned to expand these
studies.112 Other phase I trials targeting mesothelin involv-
ing either a chimeric antimesothelin monoclonal antibody
(MORAb-009), or a live-attenuated Listeria monocytogene
vector encoding human mesothelin (CRS-207) are cur-
rently running.113
Other serum markers identified recently include serum
circulating hepatocyte growth factor,91 osteopontin,90 and
simian virus 40 (SV40) T-antigen.114 Serum osteopontin
would appear to be somewhat controversial as the initial
study did not take into account the fact that osteopontin is
cleaved by thrombin in the blood,101 and a recent study in
head and neck cancer has demonstrated that different ELISA
systems used to detect osteopontin can give varying sensitiv-
ity.115 Other potential candidates emerging for the early
detection of mesothelioma identified hepatocyte growth fac-
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tor, basic fibroblast growth factor, and VEGF-beta as serum
markers which can significantly differentiate high-risk indi-
viduals from healthy and MPM groups. The same study
found that a combination of 8-hyroxy-2-deoxyguanosine
(80HdG), VEGF-beta, and SMRP as a combination of serum
markers which could predict whether the MPM was in early
or advanced stages.116
Another controversial serum marker for mesothelioma
concerns SV40.117,118 Links between asbestos exposure and
SV40 in human malignant mesothelioma have been demon-
strated,114,119,120 but other studies have been unable to iden-
tify such a link.121–123 A recent study in prediagnostic serum
samples was unable to detect the SV40 T antigen, nor was it
able to detect SV40 virus DNA.124 One possible explanation
for the disparity concerns contaminated polio vaccines which
were linked to the administration of SV40-contaminated
polio vaccines from 1954 until 1963.125 Over the 8 years of
use, of 92 million US residents who received polio vaccine,
approximately 62% received the potentially SV40-contami-
nated Salk polio vaccine and of these at least one fifth may
have received live, infectious SV40 containing vaccine.1
Advances in detection methodologies have since led to the
suggestion that the conflicting results seen for SV40 in
several studies may be due in part to difficulties in accurately
detecting SV40-T and/or poor experimental design.125,126
Indeed there is some evidence that SV40 may be also present
in the normal tissues of MPM patients.127 This would support
the clear in vitro evidence demonstrating that SV40 can act as
a cocarcinogen in mesothelial cells.128–130
Clearly, it is evident that further testing or refinements
to existing detection methods and substantial basic research
will be required to determine if SV40 T antigen plays an
important role in MPM malignancy and if tests to detect
SV40 T will prove suitable for development as an MPM
biomarker.
Overall, with the identification of new serum biomar-
kers it may be possible in the future to combine them all into
an array based serum test for mesothelioma.
Conclusions and Future Directions
Issues of Array Reliability/Overlap
One of the problems identified with the use of array
technology in MPM, has been the lack of concordance be-
tween the various predictive or prognostic studies. If one
compares all the predictive sets identified,60–62,64,65 there is
very little overlap (Figure 1). From this one can conclude that
microarray analysis of MPM would appear to be very
“noisy”, and the prognostic genes identified should be reeval-
uated individually to test for prognostic significance. Never-
theless, several of the genes identified in these predictive
array studies have also shown up in other MPM array studies.
The predictive genes for which some form of alternative array
based validation exists are listed in Table 1.
Combined meta-analysis of all available datasets could
therefore potentially identify critical genes which are in-
volved in MPM pathogenesis. Several of the published
mesothelioma gene expression array studies have been
submitted to Oncomine. This research platform suite com-
bines a rapidly growing compendium of cancer transcrip-
tome profiles with a sophisticated analysis engine and a
powerful web application for data-mining and visualiza-
FIGURE 1. Graphical comparison
of five microarray studies of malig-
nant pleural mesothelioma
(MPM)60–62,64,65 with prognostic
gene lists. Adapted with permission
from Lo´pez-Rı´os F, Chuai S, Flores
R, Shimizu S, Ohno T, Wakahara K,
Illei PB, Hussain S, Krug L, Za-
kowski MF, Rusch V, Olshen AB,
Ladanyi M. Global gene expression
profiling of pleural mesotheliomas:
overexpression of aurora kinases
and P16/CDKN2A deletion as
prognostic factors and critical eval-
uation of microarray-based prog-
nostic prediction. HYPERLINK
“javascript:AL_get(this,%20’jour’,
%20’Cancer%20Res.’);” Cancer
Res. 2006 Mar 15;66(6):2970–9,
Figure 3.
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tion.131 Meta-analysis of the mesothelioma studies may
provide more robust prognostic genes which could be
subsequently validated.
Mesothelioma and the IGF-Axis
One emerging subset of genes which has been shown to
be altered in mesothelioma concerns the insulin-like growth
factor axis.132 With microarray analysis, several members of
this axis have also been shown to be altered confirming the
importance of this pathway in mesothelioma. Two commonly
down-regulated genes from the IGF-axis in mesothelioma are
IGFB-4 and IGFBP-5.35,42,62,133 Commonly overexpressed
genes include IGFBP-2, IGFBP-3, IGFBP-7/MAC25 and an
exon specific isoform of IGF-I (IGF-I, exon 1A).60,66,68,70
Increased IGFBP-5 expression has been linked to long
term survival (12 months postoperation).62 However, in a
separate study down-regulation of IGFBP-5 was observed to
be a common feature in mesothelioma, but no survival data is
available for these samples.66 It must be noted that IGFBP-3
is another gene whose overexpression has also been linked to
poor outcome tumors,60 indicating that a comprehensive anal-
ysis of the IGFBP family may have clinical value in MPM.
Kratzke and coworkers66 noted the dysregulation of the
IGF-axis in an early microarray study, and reanalysed their
microarray data specifically for members of the IGF-axis.
They subsequently identified additional genes which were
overexpressed in mesotheliomas (IGF1R, IRS-2, IGFBP-3,
and IGFBP-6).134 IGF1R was also identified as a gene with
altered expression in mesothelioma by Albeda and cowork-
ers.67 The analysis by Hoang et al.,134 led to the discovery that
there is selective activation of the Insulin receptor substrates
-1 and -2 (IRS-1, IRS-2) associated with a distinct subset of
MPMs.
Mesothelioma as a Target for Epigenetic
Therapies
From the results of the various microarray experiments
several genes identified as being altered in mesothelioma
have either been associated with chromatin remodelling com-
plexes, or respond to treatment with inhibitors targeting the
epigenetic machinery. In particular, CRI1 (CREBBP/EP300
inhibitory protein 1, also known as EID-1) is a CREB-
binding protein identified as a significant (p  2.7  104)
potential mesothelioma tumor marker in the study by Gordon
et al.,70 This protein has been shown to antagonize the action
of pRb, p300, and CBP histone acetyltransferase activity.70
Several cell line studies have also shown that targeting
histone deacetylases can sensitize mesothelioma cells to ther-
apeutic approaches.135–138
From our evaluation of the available published microar-
ray gene lists, several genes have been shown to be altered in
cells following treatment with histone deacetylase inhibitors,
and a sample of these is provided in Table 3.
From these indicators, it is clear that histone deacety-
lase inhibitors represent a potentially new treatment modality
in MPM. Early clinical trials of Zolinza (suberoylanilide
hydroxamic acid) in mesothelioma demonstrated patient
responses.139,140 These encouraging responses have led to
the initiation of a phase clinical III trial of Zolinza in
mesothelioma.141
Methylation is another epigenetic modification which is
frequently associated with the down-regulation of gene ex-
pression in MPM.142–145 A recent study examined the pro-
moter methylation of six cell cycle control pathway genes
(APC, CCND2, CDKN2A, CDKN2B, HPPBP1, and RASSF1)
in a series of 70 MPMs. Significantly higher lung asbestos
body burden occurred if any of these cell cycle genes were
methylated (p  0.02), and there was a significant trend of
increasing asbestos body counts as the number of methylated
cell cycle pathway genes increased from 0 to 1, to 1, (p 
0.005), and remained significant after controlling for age,
gender, and tumor histology.146 These data suggest that
following asbestos exposure aberrant DNA methylation
may be the trigger for the clinical course of malignant
mesothelioma.
A phase I clinical trial of Decitabine (a DNA methyl-
transferase inhibitor) in patients which included mesotheli-
oma has recently been completed, and in 2/7 mesothelioma
patients stable disease was achieved.75
Indeed the importance of therapies targeting epigenetic
pathways is actively being explored in mesothelioam re-
search. From a query of the clinical trials database at the
ClinicalTrials website (http://clinicaltrials.gov), several phase
I/II clinical trials for both histone deacetylase inhibitors and
DNA methyltransferase inhibitors involving mesothelioma
were identified (Table 4).
Mesothelioma—Consistency for Progression to
More Deadly Profiles
Are there any overall features emerging from these
studies? If we begin by looking at the responses to cells
exposed to fibers patterns emerge indicating pathways for the
progression of these cells into more aggressive forms. Expo-
TABLE 3. Genes Identified in MPM Which Respond to HDAC Inhibition
Gene Array (Change) HDAC Inhibitor Response Reference
COL1A1 Elevated Down-regulated 70,152
Survivin Elevated Down-regulation/degradation 151,153–155
bFGF Elevated in sarcomatoid Down-regulated 66,156
VEGFR2 Down-regulated Up-regulated 35 Gray and O’Byrne, unpublished data
Cyclin D2 Down-regulated Up-regulated 35,157
bFGF, basic Fibroblast growth factor; VEGFR, vascular endothelial growth factor receptor; MPM, malignant pleural mesothelioma; HDAC, histone deacetylase; COL1A1,
collagen type 1 alpha-1.
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sure to fibers causes the up-regulation of antiapoptotic, proan-
giogenic, proinflammatory, and prosurvival pathways cou-
pled with the suppression of pathways linked to cell mediated
immunity. Are these pathways also affected in other array
studies? Antiapoptotic pathways have been shown to be
affected in several independent studies.35,70,74,133,147 Prosur-
vival pathways have been shown to be affected in several
studies,38,64,69 while cell mediated immunity,41 proangio-
genic,70 and proinflammatory62 pathways have also been
observed to be altered.
Final Comments
What if anything, can we conclude from the plethora of
data on MPM emerging from array based technologies?
Clearly, there is an implicit gain in the identification of novel
potential prognostic or biomarkers, which can individually be
worked up for independent validation. The concern for many
researchers and regulatory bodies would be the lack of
concordance between studies. Nevertheless continued meta-
analysis of the already generated data along with any new
data may prove fruitful, or the development of a concerted
multicenter study to conduct large scale microarray or pro-
teomic analysis of a defined set of mesothelioma samples.
An additional avenue of approach may be to collate and
subject all the currently available data to a “systems biology”
analysis,148 to identify networks of MPM interactions/path-
ways which might allow for the identification of new thera-
peutic approaches to the treatment of MPM.
Recently, suggestions have been made to develop a
Mesothelioma Virtual Tissue Bank.149,150 These initial sug-
gestions have centered on the need for “Common Data
Elements” in relation to the annotation of samples in bio-
repositories. A multitiered approach to enhance this could be
achieved by incorporating and linking samples to other data-
sets such as those stored in Oncomine.131 If further mesothe-
lioma databases were to emerge (e.g., proteomic studies etc),
which could be linked into a central virtual tissue bank,
combined meta-analysis may allow researchers to quickly
identify important targets/candidate genes in mesothelioma.
The continued paucity of treatment options with good clinical
outcome for MPM means that significant research remains to
discover biomarkers for the early detection of MPM, and the
identification and validation of druggable targets or prognos-
tic indicators for the treatment of MPM. Array technology
represents a unique way to maximize such discoveries. Com-
binations of array techniques to combine both gene expres-
sion and protein profiling may help to narrow down such
potential targets.
This review has described how array technology has
revolutionized our current knowledge of mesothelioma but
much clearly remains to be done to improve the diagnosis and
management of this disease.
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